Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Palmitoylethanolamide a day

Phase 2Small molecule

NNavy Medical Center San Diego

Palmitoylethanolamide a day is one of 2 small molecule programs targeting Palmitoylethanolamide. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

PalmitoylethanolamideRecruiting

PalmitoylethanolamidePhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Palmitoylethanolamide

#DrugCompanyPhaseTrials

Palmitoylethanolamide a day

NNavy Medical Center San Diego

Palmitoylethanolamide

TThe University of Texas Health Science Center, Houston

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Palmitoylethanolamide1 trial

Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

Recruiting·NNavy Medical Center San Diego·Phase 2·NCT06273462·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Palmitoylethanolamide a day. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Palmitoylethanolamide a day compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Palmitoylethanolamide a day. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Navy Medical Center San Diego company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNavy Medical Center San Diego

Related News